Preliminary study of selective estrogen modulators (SERMs) combined with maximum androgen blockade for metastatic prostate cancer

Preliminary study of selective estrogen modulators (SERMs) combined with maximum androgen blockade for metastatic prostate cancer - SERMs for metastatic PCA

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006400

Enrollment

Registered

2011-09-25

Start date

2010-05-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bone metastatic prostate cancer

Interventions

androgen deprivation therapy raloxifene toremifene

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: prostate cancer diagnosed by prostate biopsy, Over 20 years old male with bone metastasis confirmed CT scan or bone scintigraphy, written informed consent

Exclusion criteria

Exclusion criteria: Liver dysfunction, thrombosis, using bisphosphonate, warfarin, phenobarbital, rifampicin, or ampicillin. Urinary tract infection, mental disease, the patients decided not applicable for this study by physician

Design outcomes

Primary

Measure	Time frame
PSA-relapse-free survival	—

Secondary

Measure	Time frame
VAS, and QOL	—

Countries

Japan

Contacts

Public ContactTetsuya Fujimura

the University of Tokyo Department of Urology

fujimurat-uro@h.u-tokyo.ac.jp0338155411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026